CannBioRx Life Sciences Corp. (ATNFW)

USD 0.01

(5.63%)

Net Debt Summary of CannBioRx Life Sciences Corp.

CannBioRx Life Sciences Corp.'s latest annual net debt in 2023 was -655.73 Thousand USD , up 88.35% from previous year.
CannBioRx Life Sciences Corp.'s latest quarterly net debt in 2024 Q1 was 112.9 Thousand USD , up 117.22% from previous quarter.
CannBioRx Life Sciences Corp. reported annual net debt of -5.63 Million USD in 2022, up 10.16% from previous year.
CannBioRx Life Sciences Corp. reported annual net debt of -6.26 Million USD in 2021, down -474.61% from previous year.
CannBioRx Life Sciences Corp. reported quarterly net debt of 112.9 Thousand USD for 2024 Q1, up 117.22% from previous quarter.
CannBioRx Life Sciences Corp. reported quarterly net debt of -655.73 Thousand USD for 2023 FY, up 88.35% from previous quarter.

Annual Net Debt Chart of CannBioRx Life Sciences Corp. (2023 - 2017)

Historical Annual Net Debt of CannBioRx Life Sciences Corp. (2023 - 2017)

Year	Net Debt	Net Debt Growth
2023	-655.73 Thousand USD	88.35%
2022	-5.63 Million USD	10.16%
2021	-6.26 Million USD	-474.61%
2020	1.67 Million USD	-51.44%
2019	3.44 Million USD	707.34%
2018	-567.22 Thousand USD	-32.41%
2017	-428.39 Thousand USD	0.0%

Year	Net Debt	Net Debt Growth
2024 Q2	-704 Thousand USD	-723.56%
2024 Q1	112.9 Thousand USD	117.22%
2023 FY	-655.73 Thousand USD	88.35%
2023 Q2	-1.39 Million USD	21.47%
2023 Q1	-1.77 Million USD	68.47%
2023 Q3	-2.3 Million USD	-65.52%
2023 Q4	-655.73 Thousand USD	71.58%
2022 Q3	-3.15 Million USD	-351.01%
2022 Q4	-5.63 Million USD	-78.71%
2022 Q2	-698.58 Thousand USD	83.53%
2022 Q1	-4.24 Million USD	32.3%
2022 FY	-5.63 Million USD	10.16%
2021 FY	-6.26 Million USD	-474.61%
2021 Q1	-4.23 Million USD	-353.35%
2021 Q2	-201.42 Thousand USD	95.25%
2021 Q3	-11.27 Million USD	-5497.67%
2021 Q4	-6.26 Million USD	44.42%
2020 Q4	1.67 Million USD	-25.53%
2020 Q3	2.24 Million USD	-32.36%
2020 Q2	3.32 Million USD	3882.6%
2020 Q1	83.39 Thousand USD	-97.58%
2020 FY	1.67 Million USD	-51.44%
2019 FY	3.44 Million USD	707.34%
2019 Q4	3.44 Million USD	44.0%
2019 Q3	2.39 Million USD	14135.98%
2019 Q2	-17.04 Thousand USD	-103.0%
2019 Q1	567.22 Thousand USD	200.0%
2018 Q1	-340.08 Thousand USD	20.61%
2018 FY	-567.22 Thousand USD	-32.41%
2018 Q4	-567.22 Thousand USD	-9.26%
2018 Q3	-519.13 Thousand USD	4.4%
2018 Q2	-543.05 Thousand USD	-59.68%
2017 FY	-428.39 Thousand USD	0.0%
2017 Q2	-577.61 Thousand USD	0.0%
2017 Q3	-453.52 Thousand USD	21.48%
2017 Q4	-428.39 Thousand USD	5.54%

Peer Net Debt Comparison of CannBioRx Life Sciences Corp.

Name	Net Debt	Net Debt Difference
BIMI International Medical Inc.	3.11 Million USD	121.026%
China Jo-Jo Drugstores, Inc.	10.34 Million USD	106.338%
Harrow Health, Inc. 8.625% Senior Notes due 2026	116.41 Million USD	100.563%
Harrow Health, Inc. 11.875% Senior Notes due 2027	109.08 Million USD	100.601%
Leafly Holdings, Inc.	13.79 Million USD	104.754%
Leafly Holdings, Inc.	13.79 Million USD	104.754%
LifeMD, Inc.	-14.21 Million USD	95.387%
LifeMD, Inc.	-14.21 Million USD	95.387%
TRxADE HEALTH, Inc.	6.95 Million USD	109.432%
PetMed Express, Inc.	-53.84 Million USD	98.782%
Walgreens Boots Alliance, Inc.	8.23 Billion USD	100.008%